Lv01
0 积分 2025-07-17 加入
Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT
2小时前
待确认
How I treat AML relapse after allogeneic HSCT
2小时前
已完结
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial
2个月前
已完结
Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs
4个月前
已完结
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
5个月前
已完结
Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial
8个月前
已完结
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
9个月前
已完结
How I treat higher-risk MDS
10个月前
已完结
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes
11个月前
已完结
Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes
1年前
已完结
皖公网安备34019202002308
